Piper Sandler lowered the firm’s price target on NeoGenomics (NEO) to $11 from $12 following quarterly results. The firm keeps an Overweight rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- Watch Out! Analysts Have Recently Downgraded These Stocks
- NeoGenomics Faces Revenue Guidance Cut and Growth Challenges, Analyst Maintains Hold Rating
- NeoGenomics Earnings Call: Growth Amid Challenges
- Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls
- NeoGenomics price target lowered to $8 from $10 at Morgan Stanley